(Q74185683)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

post-transplant lymphoproliferative disorder

9 November 2019

main subject

0 references

1 reference

N D Zilz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

L J Olson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

C G McGregor

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 July 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Heart and Lung Transplantation

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

770-772

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Clinical applications of anti-CD20 antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Anti-CD20 monoclonal antibody therapy in Epstein-Barr Virus-associated B cell lymphoma following lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid o

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

Epstein-Barr virus-driven gene therapy for EBV-related lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2800%2900326-0

7 January 2021

10.1016/S1053-2498(00)00326-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11448808%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference